- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00344916
Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis
July 10, 2006 updated by: Regional Hospital Holstebro
NO-Synthesis in Patients With Liver Cirrhosis: Effect of L-NMMA on Renal Hemodynamics, Sodium Excretion and Plasma Levels of Vasoactive Hormones
Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls.
It is hypothesized that nitric oxide availability is increased in liver cirrhosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In a randomized, placebo controlled design the acute effects of Ng-monomethyl-L-arginine are studied on:
- renal hemodynamics (GFR and RPF)
- blood pressure and heart rate
- lithium clearance
- plasma levels of vasoactive hormones
Study Type
Interventional
Enrollment
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Healthy controls
- Age 20 to 60 years
- Both men and women
- Weight below 100 kg
- Normal clinical examination and laboratory screening
- Fertile women only if using contraception
- Informed consent according to the regulations of the local ethics committee
Liver cirrhosis
- Biopsy verified liver cirrhosis or clinical and laboratory signs of liver cirrhosis including hypoalbuminaemia, increased prothrombin time in combination with esophagusvarices or ascites
- P-creatinine < 250 µmol/L
- Age 20-60 years
- Both men and women
- Fertile women only if using contraception
- Body weight below 100 kg
- Informed consent according to the regulations of the local ethics committee
Exclusion Criteria:
Healthy controls
- History or clinical evidence of diseases of the heart and blood vessels, kidneys, liver and pancreas, endocrine organs, lungs, neoplastic disease, myocardial infarction or cerebrovascular insult as evaluated by clinical examination and laboratory screening
- Current medication
- Drugs or alcohol abuse
- Pregnancy
- Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances
- Donation of blood less than 1 month before the experiments
Liver cirrhosis
- Apart from liver cirrhosis no history of diseases of the heart and blood vessels, endocrine organs, lungs, myocardial infarction, cerebrovascular insult or neoplastic disease.
- Drugs or alcohol abuse
- Pregnancy
- Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Erling B Pedersen, Professor, Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
June 24, 2006
First Submitted That Met QC Criteria
June 24, 2006
First Posted (ESTIMATE)
June 27, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
July 11, 2006
Last Update Submitted That Met QC Criteria
July 10, 2006
Last Verified
June 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MED.RES.HOS.1996.04.JNB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Clinical Research Network - SCReNWithdrawn
Clinical Trials on Ng-monomethyl-L-arginine (drug)
-
Medical University of ViennaTerminatedOcular Physiology | Regional Blood FlowAustria
-
Regional Hospital HolstebroCompleted
-
Regional Hospital HolstebroCompleted
-
Regional Hospital HolstebroCompleted
-
Regional Hospital HolstebroCompleted
-
Mayo ClinicAmerican Diabetes AssociationCompleted
-
Regional Hospital HolstebroAarhus University HospitalUnknownEssential HypertensionDenmark
-
VA Office of Research and DevelopmentRecruitingCardiovascular Disease | AgingUnited States
-
The Methodist Hospital Research InstituteActive, not recruitingNon-Small Cell Lung Cancer | DNA Repair-Deficiency Disorders | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma Bladder | Classical Hodgkin Lymphoma | Malignant MelanomaUnited States
-
University of AarhusCompletedDiabetic Maculopathy | Diabetes Mellitus Type 1Denmark